Article Versions Notes

Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A, Francalanci M, Taccetti G, Buonaurio S, Celardo A, et al. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study. Journal of Clinical Medicine. 2022; 11(4):1021. https://doi.org/10.3390/jcm11041021

Carnovale, Vincenzo, Paola Iacotucci, Vito Terlizzi, Carmela Colangelo, Lorenza Ferrillo, Angela Pepe, Michela Francalanci, Giovanni Taccetti, Serena Buonaurio, Assunta Celardo, and et al. 2022. "Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study" Journal of Clinical Medicine 11, no. 4: 1021. https://doi.org/10.3390/jcm11041021

Carnovale, V., Iacotucci, P., Terlizzi, V., Colangelo, C., Ferrillo, L., Pepe, A., Francalanci, M., Taccetti, G., Buonaurio, S., Celardo, A., Salvadori, L., Marsicovetere, G., D’Andria, M., Ferrara, N., & Salvatore, D. (2022). Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study. Journal of Clinical Medicine, 11(4), 1021. https://doi.org/10.3390/jcm11041021